Success of Ipsen's inaugural €500 million bond issue

Biopharmaceutical company Ipsen announced the successful completion of its inaugural €500 million bond offering. The offering, with a coupon of 3.875% and maturing in March 2032, was well received by the market, benefiting from oversubscription by diversified institutional investors. The offering follows the assignment of investment-grade ratings by S&P (BBB-) and Moody's (Baa3), with a stable outlook.

Ipsen's Chief Financial Officer, Aymeric Le Chatelier, expressed his satisfaction with this positive reception, emphasizing that this move is part of a disciplined financial approach. This issue will contribute to the company's refinancing plan, which also includes the renewal of a €1.5 billion syndicated credit line.